AOD 9604: Research on the GH Fragment

Growth hormone does a lot of things in the body. It supports tissue growth, it changes how cells handle glucose, and it pushes fat cells to release stored energy. Researchers who wanted the fat releasing effect without the rest of that list eventually landed on a small piece of the hormone called AOD 9604. It has been studied for two decades and it has never reached market approval as an obesity drug.

Here is what the published research actually supports, and where it stops.

A fragment, not the whole hormone

Human growth hormone is a 191 amino acid protein. AOD 9604 corresponds to just the last stretch of that chain, positions 176 through 191, with an added tyrosine at one end to help the molecule hold together outside the body. Researchers call the natural version of this piece the C terminal fragment, and it is the same region referenced in HGH Fragment 176 191 research.

The idea behind isolating this fragment was straightforward. Full length growth hormone raises blood sugar and can push cells toward growth in ways that matter for people with a history of certain tumors. The C terminal region was thought to carry the hormone's fat metabolizing signal without those other effects. A synthetic, stabilized version of that fragment became AOD 9604, developed originally by an Australian biotech group in the early 2000s specifically as an obesity candidate rather than a growth hormone replacement.

An early review of the compound's development described this rationale in detail, laying out why researchers expected fat cell activity without the metabolic side effects tied to intact growth hormone (Wilding, 2004).

What the fat metabolism research shows

The core claim behind AOD 9604 is that it can trigger lipolysis, the process where fat cells break down stored triglycerides for release, without meaningfully affecting insulin sensitivity or IGF 1 levels the way full growth hormone does. This is a preclinical and early pharmacology claim built on the compound's design and the animal and cell work that supported its move into human testing.

That 2004 review situates AOD 9604 among a small group of metabolic drug candidates being investigated for this kind of targeted lipolytic activity, distinct from stimulant based or appetite suppressing weight loss approaches (Wilding, 2004). It is worth being precise here: this describes the pharmacological rationale and the state of the pipeline at the time, not a confirmed human outcome. The step from a plausible mechanism to a working weight loss drug in people is exactly where AOD 9604 ran into trouble.

Human trial history

AOD 9604 moved through a conventional drug development pathway for a period. It was tracked as an active obesity candidate in pharmaceutical pipeline reviews through the mid 2000s, alongside other compounds being tested for metabolic effects at that stage of clinical development (Halford, 2006).

The compound reached phase II human trials under its original developer. Reported results did not show weight loss that separated clearly from placebo at a level that supported continuing toward approval. That outcome is consistent with how the compound is discussed in the broader obesity drug pipeline literature from that era: as a candidate that generated real pharmaceutical investment and trial infrastructure, but one whose human efficacy data did not hold up to the promise of the earlier mechanistic work (Halford, 2006).

No large phase III obesity trial for AOD 9604 has been published, and the compound has no approved indication anywhere. What circulates today under this name is sold strictly as a research chemical, not as a regulated medication.

A second life in anti doping science

AOD 9604's story took an unexpected turn outside the obesity field. Because it is derived from growth hormone, anti doping scientists wanted to know whether it could be used to blunt or evade the standard test for GH doping in sport, and whether existing assays could even detect it.

Testing showed that AOD 9604 does not interfere with the World Anti Doping Agency's isoform based growth hormone immunoassay, meaning it does not act as a masking agent for that particular test (Orlovius et al., 2013). That finding did not end the question, though. Analytical chemists still needed a way to directly detect AOD 9604 itself if athletes were using it as a compound in its own right, separate from natural growth hormone. Researchers developed mass spectrometry based methods to identify the fragment and studied how it breaks down in the body, work that now sits inside the broader toolkit used for detecting emerging, non approved peptides in sports drug testing (Cox et al., 2015; Schänzer et al., 2017).

This detection literature is some of the more rigorous published work on AOD 9604 available today, even though it answers a testing question rather than an efficacy question. It confirms the compound is real, measurable, and metabolized in a traceable way. It says nothing about whether it works as a fat loss agent in people.

Where the evidence runs thin

Recent reviews of peptide use in sports medicine and orthopedics place AOD 9604 in a familiar category: a compound with real preclinical rationale and a genuine but incomplete human trial record, now circulating in research and unregulated markets well past the point where its original developer moved on. A 2026 review of peptide therapies used around musculoskeletal injury and athletic performance lists AOD 9604 among agents lacking the large scale, high quality trial base needed to support real world efficacy or safety claims (Mendias et al., 2026). A parallel review covering peptides in orthopedic practice raises the same caution, noting that many peptides used off label, including growth hormone derived ones, have not been through the kind of trial process that would justify clinical use (Rahman et al., 2026).

Put plainly: the mechanistic case for AOD 9604 was published two decades ago, the human obesity trials that followed did not confirm it, and no regulator has approved it for any use since. What is left is a well documented research history, a solid detection literature for testing purposes, and a gap where a convincing human efficacy trial should be.

If you are trying to compare AOD 9604 against other researched metabolic peptides, LifeConverted's peptide reference library lays out what is documented for each compound side by side.

Common questions

What is AOD 9604 exactly? It is a synthetic fragment of the tail end of human growth hormone, amino acids 176 to 191, with an added tyrosine that stabilizes the molecule. It was designed to isolate the fat metabolizing region of the hormone from the parts that drive tissue growth.

Did AOD 9604 get approved as a weight loss drug? No. Phase II trials did not show weight loss meaningfully better than placebo, and the original developer's obesity program did not continue past that stage. It is not approved by the FDA or any major regulator and is sold today only as a research compound.

Why does AOD 9604 show up in anti doping research? Because it comes from growth hormone, scientists checked whether it could interfere with standard GH doping tests. Studies found it does not affect the main WADA isoform assay, which led to separate detection methods being developed for it specifically.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.